TABLE 2.
Drugs administered to hospitalized patients stratified according to disease severity
| All patients (n = 40) | Nonsevere patients (n = 21) | Severe patients (n = 19) | |
|---|---|---|---|
| Azithromycin | 26 (65%) | 15 (71.4%) | 11 (57.9%) |
| Other antibiotics | 40 (100%) | 21 (100%) | 19 (100%) |
| Azole antifungals | 1 (2.5%) | 0 (0%) | 1 (5.3%) |
| Lopinavir-ritonavir | 4 (10%) | 1 (4.8%) | 3 (15.8%) |
| Hydroxychloroquine | 15 (37.5%) | 8 (38.1%) | 7 (36.9%) |
| Tocilizumab | 4 (10%) | 1 (4.8%) | 3 (15.8%) |
| High-dose corticosteroidsa | 14 (35%) | 5 (23.8%) | 9 (47.4%) |
| Management of immunosuppression | |||
| MMF/MPA withdrawal | 34/34 (100%) | 17 (100%) | 15 (100%) |
| Calcineurin inhibitors withdrawal | 15/35 (42.6%) | 2 (11.8%) | 13 (72.2%) |
| mTOR inhibitors withdrawal | 6/6 (100%) | 4 (100%) | 2 (100%) |
| Delayed belatacept administration | 1 (2.5%) | 1 (4.8%) | 0 (0%) |
MMF, mycophenolate mofetil; MPA, mycophenolic acid; mTOR, mammalian target of rapamycin.
a
High-dose corticosteroids included intravenous dexamethasone and intravenous methylprednisolone. Continuous variables are presented as medians (interquartile ranges), whereas categorical variables are given as counts (percentages).